FDA’s Orphan Exclusivity Requirement For “Clinical Superiority” Challenged In Court

Depomed argues in a suit against FDA that it should not have to show Gralise (gabapentin) is clinically superior to Neurontin since Neurontin never received an orphan drug designation or orphan exclusivity.